Verus Capital Partners LLC Sells 11,610 Shares of Scholar Rock Holding Corporation $SRRK

Verus Capital Partners LLC lowered its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 52.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,490 shares of the company’s stock after selling 11,610 shares during the period. Verus Capital Partners LLC’s holdings in Scholar Rock were worth $516,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Redmile Group LLC boosted its stake in Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock worth $445,715,000 after buying an additional 3,845,775 shares in the last quarter. Orbis Allan Gray Ltd raised its position in Scholar Rock by 1,034.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock worth $151,044,000 after purchasing an additional 3,126,677 shares during the period. Wellington Management Group LLP lifted its stake in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after purchasing an additional 2,521,022 shares during the last quarter. Norges Bank purchased a new position in shares of Scholar Rock in the fourth quarter worth about $91,603,000. Finally, Siren L.L.C. grew its position in Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after acquiring an additional 1,575,008 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Scholar Rock

In related news, Director Katie Peng sold 5,446 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the sale, the director owned 34,301 shares of the company’s stock, valued at $1,848,137.88. The trade was a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joshua Reed sold 3,053 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the sale, the director owned 19,518 shares in the company, valued at approximately $1,048,897.32. This trade represents a 13.53% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 17,149 shares of company stock worth $923,108 over the last 90 days. 10.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SRRK. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Canaccord Genuity Group started coverage on Scholar Rock in a research note on Monday, April 20th. They issued a “buy” rating and a $62.00 target price on the stock. HC Wainwright increased their price objective on Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Friday, July 17th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $58.00 price target on shares of Scholar Rock in a research note on Tuesday, July 21st. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $56.21.

Scholar Rock Trading Down 0.0%

SRRK opened at $47.29 on Monday. The stock has a market cap of $5.67 billion, a PE ratio of -13.17 and a beta of 0.67. The business has a 50 day moving average of $50.11 and a 200-day moving average of $47.72. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $58.49. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period last year, the company posted ($0.67) earnings per share. Equities research analysts predict that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).